The GEIR (Grupo español de Ictus Retina) Registry: Rationale and Design of the First Nationwide Multicentre Retinal Stroke Registry in Spain (GEIR)

November 3, 2026 updated by: Susana M Ruiz Bilbao, Germans Trias i Pujol Hospital

Rationale and Design of the GEIR Registry: a Nationwide Multicentre Study of the Natural History, Epidemiological, Neurovascular, Imaging and Therapeutic Aspects of Retinal Stroke in Spain

Retinal stroke is a time-dependent neurovascular emergency associated with severe visual loss, increased risk of cerebrovascular events and substantial variability in clinical management.

The GEIR Registry is a nationwide, multicentre, ambispective observational registry comprising retrospective and prospective data collected from participating hospitals throughout Spain.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Despite growing recognition of retinal artery occlusion as the ocular equivalent of acute ischaemic stroke, important uncertainties remain regarding its epidemiology, pathophysiology, healthcare delivery, retinal viability and optimal treatment strategies. Current evidence is largely derived from retrospective cohorts, single-centre studies and a limited number of randomised clinical trials. Furthermore, no nationwide multicentre retinal stroke registry currently exists in Spain. The GEIR Registry was established to address these knowledge gaps through the creation of a national clinical and translational research platform dedicated to retinal stroke.

Methods and analysis The GEIR Registry is a nationwide, multicentre, ambispective observational registry comprising retrospective and prospective data collected from participating hospitals throughout Spain.

Consecutive patients presenting with retinal stroke, including central retinal artery occlusion, branch retinal artery occlusion, cilioretinal artery occlusion and paracentral acute middle maculopathy, are eligible for inclusion.

Clinical information is collected using a the institution's REDCap electronic data base specifically designed for the registry and includes demographic characteristics, vascular risk factors, acute stroke pathway metrics, neurovascular investigations, reperfusion therapies, laboratory biomarkers, secondary prevention strategies, neurological outcomes, ophthalmological assessments and longitudinal optical coherence tomography (OCT) biomarkers.

The registry aims to characterise retinal stroke epidemiology, healthcare delivery and long-term outcomes, while providing a unique platform for investigating retinal ischaemia, imaging biomarkers of retinal viability and predictors of visual recovery. Statistical analyses include descriptive epidemiological analyses, multivariable regression models and longitudinal outcome assessments.

Ethics and dissemination The registry will be conducted in accordance with the Declaration of Helsinki, applicable European and Spanish data protection regulations and local ethics committee approvals. Written informed consent will be obtained for prospective participants. Data will be pseudonymised and stored within a secure REDCap infrastructure.

Results generated from the registry will be disseminated through peer-reviewed publications, scientific conferences and collaborative multicentre research initiatives. The GEIR Registry is intended to serve as a long-term national infrastructure supporting clinical, epidemiological and translational research in retinal stroke.

Study Type

Observational

Enrollment (Estimated)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Susana Ruiz-Bilbao, MD PhD
Phone Number: 9 +34 93 4651200
Email: sruizbilbao@gmail.com

Study Locations

Spain
- Barcelona
  - Badalona, Barcelona, Spain, 08916
    - Germans Trias

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

patients affected of retinal stroke

Description

Inclusion Criteria:

Age >18 years.

Clinical diagnosis of retinal stroke.

Symptom onset or last known normal vision within the previous 24 hours.

Absence of pre-existing ocular pathology severely limiting visual acuity in the affected eye.

Exclusion Criteria:

Patient with others diseases affecting retinal examination or retinal behaviour

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Observational Models: OTHER
Time Perspectives: OTHER

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
national research registry platform Time Frame: 2026.12 - 2030.12	To establish the first nationwide retinal stroke registry in Spain.	2026.12 - 2030.12
To estimate the epidemiological burden of retinal stroke. Time Frame: 2026.12 - 2030.12	To estimate the national epidemiological burden of retinal stroke in Spain.	2026.12 - 2030.12
To characterise healthcare pathways and access to reperfusion therapies. Time Frame: 2026.12 - 2030.12	To characterise national healthcare pathways and access to reperfusion therapies in Spain	2026.12 - 2030.12
To describe the natural history of retinal stroke. Time Frame: 2026.12 - 2030.12	Retinal stroke natural history in Spain	2026.12 - 2030.12
To identify clinical, neurovascular and imaging predictors of visual recovery. Time Frame: 2026.12 - 2030.12	searching imaging predictors of visual recovery	2026.12 - 2030.12
To investigate OCT biomarkers associated with retinal viability and treatment response. [CEIC GEIR HUGTiP \| Word] and precise the time of retinal ischemia Time Frame: 2026.12 - 2030.12	searching OCT biomarkers of retinal viability	2026.12 - 2030.12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Germans Trias i Pujol Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

January 1, 2030

Study Completion (Estimated)

January 1, 2030

Study Registration Dates

First Submitted

October 21, 2026

First Submitted That Met QC Criteria

October 21, 2026

First Posted (Actual)

October 28, 2026

Study Record Updates

Last Update Posted (Actual)

November 6, 2026

Last Update Submitted That Met QC Criteria

November 3, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

GEIR-2026 GrupoEspañolIctusRet

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

IPD Plan Description

undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Studies a U.S. FDA-regulated device product

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.